While the Center for Drug Evaluation and Research's (CDER's) record-setting number of novel product approvals stole many of the end-of-year headlines in 2018, the new class of medications also set a first for orphan drugs.
Of the 59 novel drugs and therapeutic biologics CDER cleared last year, 35 (59%) were orphan products